Neumedicines Inc. of Pasadena, California, is a preclinical-stage, biopharmaceutical company focused on research and development of novel protein therapeutics that treat and support patients suffering from serious illnesses. The company’s lead candidate, HemaMax (recombinant human Interleukin-12, or rhIL-12), is a naturally-occurring signaling molecule that acts at a basic level of the hematopoietic (blood-forming) system by stimulating quiescent stem cells. In preclinical animal models, HemaMax has shown the ability to generate robust and broad hematopoietic recovery in lethally irradiated normal mice as well as in tumor bearing mice treated with radiation and chemotherapy. Neumedicines is currently advancing HemaMax as a treatment for chemotherapy- and radiation-induced thrombocytopenia as well as for Acute Radiation Syndrome.

Because HemaMax possesses both potent hematological and immunological properties, it is uniquely suitable as a hematological adjuvant cancer therapy acting to prevent and alleviate three of the major side effects of cancer treatments, namely anemia, neutropenia and thrombocytopenia.

In 2008, Neumedicines secured a prestigious contract from the Biomedical Agency Radiation Medicine Agency (BARDA) to develop Hemamax for the treatment of the Hematopoietic Syndrome related to Acute Radiation Syndrome (ARS). The Company has also has been awarded a small business grant (STTR) from National Cancer Institute (NCI) for innovative cancer therapies to develop HemaMax as a hematological adjuvant cancer therapy.

For more information contact: Lena A. Basile, Ph.D., J.D., President, Chief Scientific Officer
, Pasadena, CA 91107
neumedicines.com

(cell)
(office)